Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04523220
Registration number
NCT04523220
Ethics application status
Date submitted
20/08/2020
Date registered
21/08/2020
Titles & IDs
Public title
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
Query!
Scientific title
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study to Assess the Safety and Tolerability of Monthly Subcutaneous Administrations of a Low and High Dose Cohort of Osocimab to ESRD Patients on Regular Hemodialysis
Query!
Secondary ID [1]
0
0
2019-003957-27
Query!
Secondary ID [2]
0
0
20115
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CONVERT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
End-stage Renal Disease
0
0
Query!
Prevention of Thromboembolic Events
0
0
Query!
Hemodialysis
0
0
Query!
Hemodiafiltration
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Blood
0
0
0
0
Query!
Clotting disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BAY1213790 (Osocimab)
Treatment: Drugs - Placebo
Experimental: BAY1213790 low dose - Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end of the extension treatment period.
Placebo comparator: Placebo low dose - Placebo will be administered subcutaneously in the same manner as Osocimab.
Experimental: BAY1213790 high dose - Participants will receive Osocimab (BAY1213790) 210 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 105 mg until the end of the extension treatment period.
Experimental: Placebo high dose - Placebo will be administered subcutaneously in the same manner as Osocimab.
Treatment: Drugs: BAY1213790 (Osocimab)
Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
Treatment: Drugs: Placebo
Subcutaneous administration in the same manner as Osocimab.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Cumulative Incidence Risk of the First Composite of Major Bleeding (MB) and Clinically-relevant Non-major Bleeding (CRNMB) Events as Assessed by Blinded Central Independent Adjudication Committee (CIAC)
Query!
Assessment method [1]
0
0
Cumulative incidence risk of the first Composite of MB and CRNMB (ISTH) at month 6 is reported in the table.
Descriptive time to composite of MB and CRNMB Events is reported in statistical analysis.
Descriptive time to composite of treatment emergent major and CRNMB events \[in alignment with International Society on Thrombosis and Haemostatsis (ISTH) guidelines\] analyses were performed. The cumulative incidence function for the event-of-interest together with the corresponding confidence interval were estimated for each treatment arm using Aalen-Johansen estimators. Cumulative incidence of events up to the day, inclusive.
Query!
Timepoint [1]
0
0
From the first dose of study intervention up till 30 days after last study intervention in the main treatment period, up to 6 months
Query!
Primary outcome [2]
0
0
Cumulative Incidence Risk of Composite of Moderate and Severe Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [2]
0
0
Cumulative incidence risk of composite of moderate and severe AEs and SAEs at month 6 is reported in the table.
Descriptive time to the composite of Moderate and Severe AEs and SAEs is reported in statistical analysis.
An AE was any untoward medical occurrence in a patient or clinical study participant, whether or not considered related to the study intervention.
Query!
Timepoint [2]
0
0
From the first dose of study intervention up until 30 days after last study intervention in the main treatment period, up to 6 months
Query!
Secondary outcome [1]
0
0
Ratio of Activated Partial Thromboplastin Time (aPTT) at 6 Months Trough Levels Versus Baseline.
Query!
Assessment method [1]
0
0
The aPTT at trough levels after 6 months were analyzed as ratio to baseline by providing the Geometric Mean (Standard Deviation).
aPTT was measured via the kaolin-trigger method (clotting assay).
Query!
Timepoint [1]
0
0
At 6 months (Visit 19 / Day 30 of the 6th month)
Query!
Secondary outcome [2]
0
0
Ratio of Factor XI (FXI) Activity at 6 Months Trough Levels Versus Baseline
Query!
Assessment method [2]
0
0
The Factor XI (FXI) activity at trough levels after 6 months were analyzed as ratio to baseline by providing the Geometric Mean (Standard Deviation).
Factor XI activity was assessed with an aPTT-based coagulation test using FXI deficient plasma.
Query!
Timepoint [2]
0
0
At 6 months (Visit 19 / Day 30 of the 6th month)
Query!
Eligibility
Key inclusion criteria
* Participants must be at least 18 years of age
* Patients with end-stage renal disease on hemodialysis (including hemodiafiltration) for =3 months, receiving dialysis at least 9 hours a week and stable in the view of the investigator
* Body weight of at least 50 kg
* Male and/or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Recent (<6 months before screening) clinically significant bleeding
* Hemoglobin (Hb) < 9.0 g/dL at screening
* Platelet count < 100 x 10^9/L
* aPTT or PT > ULN (upper limit of normal)
* Hepatic disease associated with ALT > 3x ULN, or total bilirubin >2x ULN with direct bilirubin > 20% of the total
* Sustained uncontrolled hypertension (diastolic blood pressure =100 mmHg and/or systolic blood pressure = 180 mmHg)
* Known intracranial neoplasm, arteriovenous malformation or aneurysm
* Known bleeding disorders e.g. von-Willebrand disease or Hemophilia A, B or C
* Recent (<3 months before screening) thromboembolic event, e.g. acute coronary syndrome, stroke or VTE (except dialysis access thrombosis)
* Recent (<3 months before screening) major surgery or scheduled major surgery during study participation
* Scheduled living donor renal transplant during study participation
* Persistent heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher
* Receiving antiplatelet therapy except daily ASA = 150 mg/day
* Receiving anticoagulation in therapeutic doses, other than standard anticoagulation during the hemodialysis procedure
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/08/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/05/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
704
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Sydney Adventist Hospital - Wahroonga
Query!
Recruitment hospital [2]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [3]
0
0
Eastern Health Integrated Renal Service - Box Hill
Query!
Recruitment hospital [4]
0
0
John Hunter Hospital - New Lambton Heights
Query!
Recruitment postcode(s) [1]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
2305 - New Lambton Heights
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Mexico
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Utah
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Virginia
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Kärnten
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Salzburg
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Wien
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Baudour
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Bonheiden
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Gent
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Leuven
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Liege
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Sint-niklaas
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Dupnitsa
Query!
Country [25]
0
0
Bulgaria
Query!
State/province [25]
0
0
Haskovo
Query!
Country [26]
0
0
Bulgaria
Query!
State/province [26]
0
0
Ruse
Query!
Country [27]
0
0
Bulgaria
Query!
State/province [27]
0
0
Shumen
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Vratsa
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Liberec
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Ostrava
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Plzen
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Sokolov
Query!
Country [33]
0
0
Greece
Query!
State/province [33]
0
0
Arta
Query!
Country [34]
0
0
Greece
Query!
State/province [34]
0
0
Athens
Query!
Country [35]
0
0
Greece
Query!
State/province [35]
0
0
Ioannina
Query!
Country [36]
0
0
Greece
Query!
State/province [36]
0
0
Larissa
Query!
Country [37]
0
0
Greece
Query!
State/province [37]
0
0
Thessaloniki
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Baja
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Budapest
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Hodmezovasarhely
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Keszthely
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Miskolc
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Pecs
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Ashkelon
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Haifa
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Nahariya
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Petach Tikva
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Petah Tikva
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Tiberius
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Zerifin
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Emilia-Romagna
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Lazio
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Liguria
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Lombardia
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Toscana
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Ibaraki
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Miyagi
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Niigata
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Saitama
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Tochigi
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Tokyo
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Yamaguchi
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Kumamoto
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Kyoto
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Osaka
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Yamagata
Query!
Country [67]
0
0
Lithuania
Query!
State/province [67]
0
0
Kaunas
Query!
Country [68]
0
0
Netherlands
Query!
State/province [68]
0
0
Amsterdam
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Apeldoorn
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Deventer
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Dordrecht
Query!
Country [72]
0
0
Netherlands
Query!
State/province [72]
0
0
Eindhoven
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
Rotterdam
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Kielce
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Olkusz
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Swiecie
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Warszawa
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Zyrardow
Query!
Country [79]
0
0
Portugal
Query!
State/province [79]
0
0
Leiria
Query!
Country [80]
0
0
Portugal
Query!
State/province [80]
0
0
Lisboa
Query!
Country [81]
0
0
Portugal
Query!
State/province [81]
0
0
Porto
Query!
Country [82]
0
0
Portugal
Query!
State/province [82]
0
0
Santarém
Query!
Country [83]
0
0
Portugal
Query!
State/province [83]
0
0
Aveiro
Query!
Country [84]
0
0
Russian Federation
Query!
State/province [84]
0
0
Chelyabinsk
Query!
Country [85]
0
0
Russian Federation
Query!
State/province [85]
0
0
Kolomna
Query!
Country [86]
0
0
Russian Federation
Query!
State/province [86]
0
0
Krasnodar
Query!
Country [87]
0
0
Russian Federation
Query!
State/province [87]
0
0
Mytishchi
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Orenburg
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
Petrozavodsk
Query!
Country [90]
0
0
Russian Federation
Query!
State/province [90]
0
0
St. Petersburg
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
Yaroslavl
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Yekaterinburg
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
A Coruña
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Barcelona
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Madrid
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Valencia
Query!
Country [97]
0
0
Turkey
Query!
State/province [97]
0
0
Ankara
Query!
Country [98]
0
0
Turkey
Query!
State/province [98]
0
0
Aydin
Query!
Country [99]
0
0
Turkey
Query!
State/province [99]
0
0
Istanbul
Query!
Country [100]
0
0
Turkey
Query!
State/province [100]
0
0
Kayseri
Query!
Country [101]
0
0
Turkey
Query!
State/province [101]
0
0
Kocaeli
Query!
Country [102]
0
0
Turkey
Query!
State/province [102]
0
0
Malatya
Query!
Country [103]
0
0
Ukraine
Query!
State/province [103]
0
0
Brovary
Query!
Country [104]
0
0
Ukraine
Query!
State/province [104]
0
0
Cherkasy
Query!
Country [105]
0
0
Ukraine
Query!
State/province [105]
0
0
Dnipro
Query!
Country [106]
0
0
Ukraine
Query!
State/province [106]
0
0
Ivano-Frankivsk
Query!
Country [107]
0
0
Ukraine
Query!
State/province [107]
0
0
Kharkiv
Query!
Country [108]
0
0
Ukraine
Query!
State/province [108]
0
0
Kyiv
Query!
Country [109]
0
0
Ukraine
Query!
State/province [109]
0
0
Lutsk
Query!
Country [110]
0
0
Ukraine
Query!
State/province [110]
0
0
Mykolaiv
Query!
Country [111]
0
0
Ukraine
Query!
State/province [111]
0
0
Poltava
Query!
Country [112]
0
0
Ukraine
Query!
State/province [112]
0
0
Uzhgorod
Query!
Country [113]
0
0
Ukraine
Query!
State/province [113]
0
0
Vinnytsia
Query!
Country [114]
0
0
Ukraine
Query!
State/province [114]
0
0
Zaporizhzhya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
In this study researchers want to learn about the safety of drug Osocimab at lower-dose and higher-doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins and extra fluids in the blood). Patients with kidney disease undergoing regular dialysis are at high risk for heart and blood vessels diseases. Osocimab is a human monoclonal antibody under development for the prevention of events caused by blood clots like heart attack, stroke and death due to heart or blood vessels diseases. It works by binding to and blocking the activated form of clotting factor XI which increases the formation and stability of clots. Researchers also want to find out how drug Osocimab works in human body and how the body absorbs, distributes and excretes the drug. Participants in this study will receive monthly injection of either Osocimab at a lower-dose or higher-dose or placebo (a placebo looks like a treatment but does not have any medicine in it). Both Osocimab and placebo will be injected into the tissue under the skin of the belly. Observation for each participant will last up to 23 months. Blood samples will be collected from the participants to monitor the safety and measure the blood level of the study drug.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04523220
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
There are no current plans to share data.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/20/NCT04523220/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/20/NCT04523220/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04523220